Idorsia enters into a collaboration with antares for the development of a novel self administered drug device product for selatogrel

Idorsia enters into a collaboration with antares - for the development of a novel self-administered drug-device - product for selatogrel. the companies will develop a novel drug-device product combining idorsia's p2y(sub)12(/sub) receptor antagonist, selatogrel, with the antares quickshot(r) auto-injector. idorsia is preparing for a phase 3 study to investigate the efficacy and safety of selatogrel following subcutaneous self-administration for the treatment of a suspected acute myocardial infarction (ami) in adult patients at risk of recurrent ami. idorsia ltd. (six: idia) announced that it has entered into a global agreement with antares pharma, inc. ("antares") to develop a novel drug-device product combining selatogrel, idorsia's potent, fast-acting, reversible, and highly selective p2y(sub)12(/sub) receptor antagonist with the antares subcutaneous quickshot(r) auto-injector. with almost 20 years of experience, antares has a proven track record in developing and commercializing complex drug device products that are tailored to the patient and the therapeutic need.
ATRS Ratings Summary
ATRS Quant Ranking